• Mona Bafadhel, Neil J Greening, Theresa C Harvey-Dunstan, Johanna E A Williams, Michael D Morgan, Christopher E Brightling, Syed F Hussain, Ian D Pavord, Sally J Singh, and Michael C Steiner.
• Respiratory Medicine Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK. Electronic address: mona.bafadhel@ndm.ox.ac.uk.
• Chest. 2016 Aug 1; 150 (2): 320-8.

BackgroundPatients with moderate exacerbations of COPD and the eosinophilic phenotype have better outcomes with prednisolone. Whether this outcome is similar in patients hospitalized with a severe exacerbation of COPD is unclear. We investigated the rate of recovery of eosinophilic and noneosinophilic exacerbations in patients participating in a multicenter randomized controlled trial assessing health outcomes in hospitalized exacerbations.MethodsPatients were recruited at presentation to the hospital with an exacerbation of COPD. They were stratified into groups according to eosinophilic exacerbations if the peripheral blood eosinophil count on admission was ≥ 200 cells/μL and/or ≥ 2% of the total leukocyte count. Admission details, serum C-reactive protein levels, length of stay, and subsequent rehospitalization data were compared between groups.ResultsA total of 243 patients with COPD (117 men) with a mean age of 71 years (range, 45-93 years) were recruited. The inpatient mortality rate was 3% (median time to death, 12 days; range, 9-16 days). The median absolute eosinophil count was 100 cells/μL (range, 10-1,500 cells/μL), and 25% met our criteria for an eosinophilic exacerbation; in this population, the mean length of stay (in days) was shorter than in patients with noneosinophilic exacerbations (5.0 [range, 1-19] vs 6.5 [range, 1-33]; P = .015) following treatment with oral corticosteroids and independent of treatment prior to admission. Readmission rates at 12 months were similar between groups.ConclusionsThe study patients presenting to the hospital with a severe eosinophilic exacerbation of COPD had a shorter length of stay. The exacerbations were usually not associated with elevated C-reactive protein levels, suggesting that better treatment stratification of exacerbations can be used.Trial Registryhttp://www.isrctn.com/ISRCTN05557928.Copyright © 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

41 keywords...

hide…